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Abstract
Background: Positron emission tomography (PET) identifies cancer deposits by detecting sites of
gamma emissions that are released from radioactively labeled molecules targeting tumor to
formulate a PET image. Correlating preoperative PET scans with intraoperative findings remains a
challenge. We investigated whether high-energy gamma emissions detected by a novel hand-held
PET probe would detect tumors and offer a real-time method to localize tumor intraoperatively.
Furthermore, we investigated the novel beta probe, which detects emissions at a shorter range
than gamma emissions, making them undetectable by PET scanners, but potentially valuable for
close range intraoperative detection of tumor deposits.
Methods: Six-to-eight-week-old athymic mice were injected with one of four possible tumor cell
lines: gastric, pancreas, squamous cell and breast cancer. After tumors reached at least 1 cm in size,
they were euthanized and imaged with a micro-PET imager. Hand-held gamma and beta probes
were then used in vivo and ex vivo to measure high-energy gamma and beta emissions.
Results: The portable PET probes detected high-energy gamma and beta emissions from all
tumors evaluated. These emissions were reproducible and we established that beta emissions
correlate with high-energy gamma emissions and conventional PET scans. There was a strong
positive correlation (R = 0.8) between gamma and beta counts. Beta emission showed a stronger
correlation than gamma emission with overall tissue radioactivity.
Conclusion: This study is the first to demonstrate that gamma emission detected by conventional
PET imaging correlates with beta emissions. This study shows that compared to detection of
gamma emissions, beta counts may offer superior real-time localization of tumor deposits.
Intraoperative portable PET probe may become a useful way to exploit tumor biology and PET
technology to guide real-time tissue characterization during surgery.
Published: 21 February 2009
Annals of Surgical Innovation and Research 2009, 3:2 doi:10.1186/1750-1164-3-2
Received: 16 June 2008
Accepted: 21 February 2009
This article is available from: http://www.asir-journal.com/content/3/1/2
© 2009 Strong et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Annals of Surgical Innovation and Research 2009, 3:2 http://www.asir-journal.com/content/3/1/2
Page 2 of 6
(page number not for citation purposes)
Background
Positron emission tomography (PET) scans using fluoro-
deoxyglucose (FDG), an analog of glucose labeled with
the positron-emitting fluorine-18, is based on the recogni-
tion that malignancies accumulate FDG at greater rates
than normal tissue [1]. PET scans have helped increase
accuracy of identifying occult sources of cancer and to
improve the staging of patients with potentially curable
cancer by finding distant sites of tumor spread. However,
difficulty remains in pinpointing specific sites of tumor
and identifying small cancer deposits as the resolution of
PET scans is at best about 1 cm [2]. Unsuspected intra-
abdominal disease is still frequently first detected at the
time of surgery [3]. Diagnostic laparoscopy is indicated
for staging and to determine resectability prior to exten-
sive tumor resections, however, laparoscopy is limited by
grossly visible tumor and thus the surgeon may miss
occult sites of tumor by leaving unseen tumor behind
[4,5]. Furthermore, a tool that could identify PET avid
sites in the operating room during surgery on the perito-
neal surface, in lymph nodes, or after resection of tumor
to confirm negative margins, would provide a valuable
tool for surgeons.
Currently, no hand-held tool, other than the one
described here, is able to detect both high-energy gamma
emissions like a PET scan does and beta emissions. This
beta probe detects radioactive emissions that a PET scan-
ner does not detect, partly because beta emissions only
travel millimeters from the source of radioactivity and can
not be detected by a PET scanner. Although this property
makes them undetectable by external imaging (i.e. PET),
beta emissions are an ideal target for intraoperative detec-
tion of tumor at close range and are a novel and poten-
tially useful tool for an oncologist during surgery.
A beta detector probe has been recently developed that
allows for detection of beta rays emitted by the isotopes
used for conventional PET scanning [6]. This probe is
made from a thin crystal sufficient to stop electron radia-
tion but too thin to be sensitive to gamma rays. This pro-
vides a promising means to detect intraoperative local
positron emission in the form of beta particles. Detection
of these particles would exhibit much higher local specif-
icity over gamma radiation and additionally would allow
for minimally invasive intraoperative detection that could
provide superior detection of small tumor deposits during
surgery with precision. If we can prove that beta detection
is clinically equivalent to high energy gamma detection
for identification of PET tracers and tumor, we will have
validated a new tool that can improve radionuclide-
guided surgery.
Our hypothesis is that if shorter range beta emissions are
detectable with this novel device, then gamma emissions
detected by a hand-held gamma probe should correlate
directly with beta emissions from a hand-held beta probe.
In this study, we aim to investigate the characteristics of
beta emission detected with hand-held probes in compar-
ison to detected gamma emissions and then characterize
these emissions in a biologic model, with various tumors
implanted in mice. Murine tumor models included breast,
gastric, squamous cell, and pancreatic cancer. Mice were
injected with 18F-FDG and micro-PET imaging and porta-
ble PET probe measurements of gamma and beta emis-
sions from tumor and normal tissue were correlated.
Materials
Animal tumor model
The murine studies described all comply with the regula-
tory requirements of the Institutional Animal Care and
Use Committee (IACUC), the Research Animal Resource
Center (RARC) of MSKCC, and the National Institutes of
Health (NIH) "Guide for the Care and Use of Laboratory
Animals".
Four human cancer cell lines were studied: the breast can-
cer line MCF-7, the gastric cancer line OCUM, the pancre-
atic cancer line Panc-1, and the head and neck squamous
cell carcinoma line SCC15. The OCUM gastric cancer cells
were a gift of Masakazu Yashiro (Osaka City University
Medical School Osaka, Japan) and were maintained in
DMEM with high glucose, 2 mM L-glutamine, and 0.5
mM sodium pyruvate. All other lines were obtained from
the American Type Culture Collection (Rockville, MD)
and grown in the recommended media. Cells were main-
tained in a 5% CO2 humidified incubator at 37°C and
subcultured twice weekly.
Six to 8-week old female athymic mice (20–25 g) were
housed four per cage and allowed food and water ad libi-
tum. All animal procedures were performed under
anesthesia by inhalation of 2% isoflurane. Animals were
killed by CO2 inhalation. Tumors were established by
injecting ~1 × 106 cells in 50 μl PBS into the subcutaneous
flanks. Each animal was injected with one tumor for a
total of 15 tumors injected. 5 animals were euthanized by
the animal facility to assure animal comfort. Animals were
studied once the tumor diameter reached 1 cm at a time
of 4–6 weeks. Tumor growth was checked every second to
third day.
PET probes
The high energy gamma and beta probes (IntraMedical
Imaging LLC, Los Angeles, CA) are designed to detect 511-
keV photons from positron-emitting sources (gamma
probe) and positrons (or beta rays) directly (beta probe).
The high-energy gamma and beta probes were calibrated
to accurately localize the point source of 18F-FDG and the
count rate was determined to optimize the detection ofAnnals of Surgical Innovation and Research 2009, 3:2 http://www.asir-journal.com/content/3/1/2
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the 511 keV emissions. Radioactive emissions were meas-
ured in counts per second and recorded in triplicate.
Radioisotope production and injection into mice
18F-FDG was obtained from the institutional radiophar-
macy laboratory (Nuclear Medicine Department, MSKCC,
New York, NY). Tail vein injections of 5 uCi of 18F-FDG
suspended in 0.5 cc sterile PBS were conducted under
anesthesia.
MicroPET and CT imaging
Mice were imaged 1 hour after injection with 18F-FDG.
Animals were imaged in prone position using either the
R4 or Focus 120 microPET™ dedicated small-animal PET
scanners (Concorde Microsystems, Knoxville, TN). With
transaxial fields of view of 10 cm and s axial The transaxial
field of view covered the lower half of the thorax (includ-
ing the heart) and the upper half of the abdomen. Scans
were collected with an energy window of 350–750 keV
and a coincidence timing window of 6 nsec. Data was
sorted into 2D histograms by Fourier re-binning and
transverse images were reconstructed in a 128 × 128 × 63
(R4) or 128 × 128 × 96 (Focus 120) matrices by filtered
back-projection. Images were corrected for non-uniform-
ity of scanner response, and radionuclide decay to the
time of injection. For anatomical orientation on the PET
images, CT scans were performed on a dedicated small-
animal CT scanner (X-SPECT, Gamma Medica, North-
ridge, CA).
PET probe measurements from mice and tissue 
preparation
Following imaging, all 10 animals (with pancreatic, gas-
tric, breast and squamous cell carcinoma tumors) were
sacrificed and tumors were harvested en bloc with their
surrounding tissue. Size measurements were done both in
vivo and ex vivo after tissue had been excised. Beta and
gamma measurements were done for each tumor and for
background levels in triplicate. The amount of radioactiv-
ity from the 18F-FDG source was measured via a scintilla-
tion counter to control for the amount of radiation used
per mouse. Tissue samples including heart, kidney, liver,
bowel, and muscle were then isolated and radioactivity
measured with the hand-held PET probes for both gamma
and beta emission. All counts were repeated in triplicate
and counts represent the average value obtained. All
counts were obtained with a dwell time of 0.5 seconds.
Tissue samples were then frozen in dry-ice and isopen-
tane. Frozen tissue sections of 10 μm thickness were cut
from various levels of the specimens and mounted on
poly-L-lysine slides (Fischer Scientific, Pittsburgh, PA).
Slides were placed onto an imaging phosphor plate for
autoradiography and kept stored at -20°C. Three days
later, the images were read out at 100 μm resolution using
a phosphor-plate reader (Model G-350; Bio-Rad Labora-
tories, Hercules, CA). Subsequently, Hoechst distribution
was assessed on the identical tissue sections. For this, up
to 332 images of tumors up to 2 cm in diameter were
acquired using a 5× magnification on a Zeiss Axiovert 200
M inverted stand microscope (Carl Zeiss, Inc., Oberko-
chen, Germany). The images were montaged using Meta-
morph 6.2r3 software (Universal Imaging Corporation,
Downingtown, PA). Finally, the slides were stained with
H&E, imaged under bright field, and again montaged.
Image analysis
PET image analysis was done with ASIPro™ software
(Concorde Microsystems Inc., Knoxville, TN). To verify
ROI measurements, selected tissues were harvested,
weighed, and counted in a scintillation well counter cali-
brated for 18F-FDG.
Results
The results in Figure 1 are representative PET images along
with the autoradiographic image and corresponding H&E
staining of excised tumor specimen obtained from flank
tumors of multiple tumor types, including pancreatic, gas-
tric, squamous cell and breast cancer. Panel A shows a
micro PET image from a mouse with gastric carcinoma
(demonstrated by arrow). Other areas of visualized
uptake in the micro PET images include the heart and
bladder (labeled).
Panel B and C show the autoradiographic image and H&E
section for the same tumor.
In order to establish detection of gamma and beta emis-
sions from low and high doses of radioactivity, two doses
Conventional PET imaging detects gamma waves emitted  from tumors in a murine model Figure 1
Conventional PET imaging detects gamma waves 
emitted from tumors in a murine model. Flank tumors 
of multiple tumor types (breast, pancreatic, gastric, and squa-
mous cell carcinoma) were grown in nude mice. Mice were 
injected with radiolabeled 18F and imaged 1-hour later by a 
microPET scanner. Animals were then sacrificed and tumors 
were sectioned for analysis by autoradiography and hema-
toxylin and eosin (H&E) staining. Shown is a representative 
animal PET scan with tumor highlighted by a red arrow (A), 
autoradiograph of tumor section (B), and H&E of tumor sec-
tion (C).Annals of Surgical Innovation and Research 2009, 3:2 http://www.asir-journal.com/content/3/1/2
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at 500 μCi and 5000 μCi were evaluated (Figure 2). Mul-
tiple samples of 18F-FDG were tested at the two doses and
measurements were taken using the portable PET probes
for both gamma and beta emissions at the source and at
distances up to 5 cm from the source. There was a signifi-
cant difference in counts per second obtained from the
gamma and beta probes at both the low and high doses.
To demonstrate the relationship of gamma to beta counts
in the in vivo model, measurements were graphed from
all counts obtained from the four tumor types studied in
the 10 mice. Figure 3 shows a strong positive linear corre-
lation (R = 0.8) for the in vivo model comparing gamma
and beta emissions.
To characterize the range of localization of the high-
energy gamma probes in comparison to the beta probe,
measurements were taken at incremental distances from
mouse flank tumors one hour following injection of radi-
olabeled 18F. Beta detection was nearly zero at distances
greater than 5 cm from the tumor, whereas high-energy
gamma emissions were still detectable at 15 cm from
tumor (Figure 4).
Figure 5 demonstrates the ratio of tumor over background
counts in the mouse for gamma and beta emissions.
Results for each tumor type were averaged for all mice
studied in each tumor group. For the mice with pancreas
tumors, gamma emissions were detectable at 14 times
background counts and beta emissions at 16 times back-
Portable PET probes detect gamma emission and beta emis- sion from both low and high tested doses of radiation in vitro Figure 2
Portable PET probes detect gamma emission and 
beta emission from both low and high tested doses of 
radiation in vitro. Multiple samples of radiolabeled 18F were 
obtained at two doses (500 μCi and 5000 μCi), Measure-
ments were taken using the portable probes for both gamma 
and beta emission at the source and at distances up to 5 cm 
from the source.
Beta emission directly correlates with gamma emission in all  tested tumor types in vivo (R = 0.8) Figure 3
Beta emission directly correlates with gamma emis-
sion in all tested tumor types in vivo (R = 0.8). Four 
tumor types were tested for gamma and beta emission fol-
lowing animal injection with radiolabeled 18F (n = 10 animals). 
Pancreatic, gastric, squamous cell and breast cancer cell lines 
injected subcutaneously into the murine model. Emissions 
were measured with portable probes on the tumor in vivo as 
well as on excised tumor ex vivo once tumors reached 1 cm 
in size. Beta and gamma emission directly correlated as 
determined by the Pearson correlation calculation of the R 
value.
Beta detection better pinpoints the source of radiation than  gamma detection Figure 4
Beta detection better pinpoints the source of radia-
tion than gamma detection. Beta and gamma measure-
ments were taken at incremental distances from the tumors 
1-hour following intravenous injection of radiolabeled 18F. 
Beta detection was nearly zero at distances > 5 cm from the 
source, while gamma emission was still detectable at 15 cm. 
Data from a representative animal is shown to demonstrate 
that at the spot over tumor, the beta counts are high, but 
after the probe is moved ~2 cm away from the tumor, 
counts are nearing zero. In contrast, the gamma probe 
detects emissions up to 10 cm away from the site of tumor.Annals of Surgical Innovation and Research 2009, 3:2 http://www.asir-journal.com/content/3/1/2
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ground counts. Gastric tumors in mice demonstrated
ratios with 4-fold over background for the gamma and
6.7-fold over background for the beta emissions. Squa-
mous cell tumors demonstrated an average gamma to
background ratio of 8, and beta emissions of 7.6 over
background. Gamma counts from the breast tumors were
16 times higher than background compared to 20 times
above background for the beta.
Discussion
Hand-held PET probes to detect positrons were first
described and developed by Daghighian et al [6] in 1994
as a novel method to direct intraoperative tumor localiza-
tion. Unlike low-energy gamma probes that allow for
detection of markers such as Tc99 (used for sentinel node
mapping but not for identification of tumor cells), these
positron detecting devices allow for direct detection of
radiolabeled tumor cells by detecting the same high-
energy gamma rays (511 KeV) emitted from 18F-FDG that
are utilized to produce a PET scan. In addition, the beta
probe, allows for the direct, intraoperative detection of
positrons (beta rays) at a close range (millimeters) to the
tumor of interest. This technology provides a unique com-
bination of detection devices that in a small hand-held
form can be used in the operating room to detect smaller
foci of tumor than possible by conventional PET scan-
ning. In addition, the ability to use this technology as a
real-time device before, during and after resection of
tumor to identify additional tumor deposits, lymph nodes
and clear resection margins, would provide a valuable and
feasible tool to improve cancer resections.
The gamma probe, although useful for open resections,
can not be made smaller than a 12 mm diameter, due to
the heavy collimation needed to shield side-scatter from
the high-energy particles. For this reason, the beta probe is
of particular interest because of its potential to be pro-
duced in a small form that can be used through a 5 mm
laparoscopic port site.
Several papers have discussed the use of the high-energy
gamma probes in the operative setting, discussing their
ability to help the surgeon identify tumors during proce-
dures and results are promising [7-9]. The purpose of this
study is to establish that the positron-detecting beta probe
is able to detect tumor sites with equivalent reliability as
the more bulky gamma probe. The results from our study
demonstrate that the beta probe appears to be more spe-
cific than the gamma probe as it identifies tumor at closer
ranges (within cms) and correlates reliably with readings
obtained from the more conventional gamma emissions.
We found that the gamma probe is sensitive however,
detects counts up to ~10–15 cm from an in vitro test
source, while the beta probe is similarly very sensitive and
additionally has a shorter range of detection from the test
source. This demonstrates that the gamma probe may not
be as specific in identifying smaller tumor deposits as the
smaller, more precise properties demonstrated by the beta
probes, due to gamma ray scatter that is detectable cen-
timeters from the direct source. This property makes the
beta detector valuable for evaluation of small tumor
deposits such as lymph nodes of interest (such as in gas-
tric cancer operations) or for peritoneal disease spread (as
in pancreatic cancer). Although this study has helped to
establish a range of usability for this technology the limit
of detectability for the probes needs to be studied in fur-
ther experiments.
To evaluate the relationship of beta and high-energy
gamma counts to one another, direct counts were
obtained in triplicate from various sources of 18F-FDG. We
were able to demonstrate the relative comparison
between high-energy gamma and beta emissions. We
found gamma counts were roughly three to five times
higher than beta counts with different in vitro test dose lev-
els, establishing that beta counts have a consistent rela-
tionship to gamma counts and can be reliably used to
detect radioactive tracer. This demonstrates that the
probes are able to measure tumor counts from the 500
uCi to the 5000 uCi range and still maintain differentia-
tion in measurements.
The utility of the beta probe in the biologic murine model
was evaluated by testing mice implanted with four differ-
ent human cancer lines; pancreatic, gastric, breast and
squamous cell. We aimed to evaluate whether background
interference inherent in a biologic model would alter the
reliability and specificity of the gamma and beta probes.
We demonstrated that gamma and beta emissions
strongly correlate with a correlation coefficient of 0.8, in a
manner very similar to the in vitro experiments. Evalua-
Ratio of gamma and beta counts to background counts in vivo  in mice with pancreatic, gastric, breast, and squamous cell  tumors Figure 5
Ratio of gamma and beta counts to background 
counts in vivo in mice with pancreatic, gastric, breast, 
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tion of four tumor types in terms of the ratio of counts
from the tumor itself compared to background counts
from the mouse permitted calculation of ratios that are
reproducible and demonstrate feasibility of using these
probes intraoperatively. On average, high-energy gamma
counts were between 4 and 16-fold higher than back-
ground counts over four different tumors tested and
allowed for good identification of tumor sites. Beta counts
were consistently 7 to 20-fold over background counts,
making identification of tumor sites feasible. Interest-
ingly, the breast cancer tumors had the highest ratio of
beta counts. These animals were placed in the PET scanner
an average of 80–90 minutes after injection of 18F-FDG
compared to 60 minutes for the other tumors evaluated.
It is possible that this increased interval to scanning and
measurement with high-energy gamma and beta emis-
sions, altered background levels of 18F-FDG compared to
tumor uptake, causing an altered differential between
tumor and background. This question of whether timing
of gamma and beta measurement from the time of 18F-
FDG injection alters tumor to background ratio, will be
answered by future studies. The characterization of ratios
of detection for the two probes in various types of tumor
is very helpful as it validates the ability to detect these
tumors in comparison to background uptake of radioac-
tivity.
Conclusion
In summary, this study demonstrates that the beta probe
allows for detection of tumor and correlates with high-
energy gamma probes in a reliable and reproducible man-
ner. In addition, we have demonstrated that the beta
probe may provide increased sensitivity over the gamma
probe, as it may be able to identify smaller sites of tumor.
The utility of this in the operating room would be para-
mount. Not only could real-time intraoperative detection
and confirmation of tumor be possible, but evaluation of
additional, unseen deposits of tumor will be possible. In
this study, we were able to easily identify tumors that were
implanted in this murine model, but we have yet to estab-
lish the lowest detectable limit in vivo. Further studies of
this promising technology are warranted and will estab-
lish the role of hand-held PET probes in the resection of
cancer.
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